GPT and Hypertension: Combination therapy with cabozantinib and nivolumab did cause more grade 3 or 4 adverse events than sunitinib monotherapy (60.6% vs. 50.9%) with hypertension, diarrhea, and various lab abnormalities (hyponatremia, hypophosphatemia, and AST/ALT abnormalities) being most frequently experienced.